Abcam, ab302634, Anti-ASAH1 antibody [23/Acid Ceramidase] - BSA and Azide free

Size: 100µg / 1mg
Mouse Recombinant Monoclonal ASAH1 antibody. Carrier free. Suitable for WB and reacts with Human samples.
Key facts
Host species:Mouse,
Clonality:Monoclonal,
Clone number:23Acid Ceramidase,
Isotype:IgG1,
Carrier free:Yes,
Reacts with:Human,
Applications:WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Want a custom formulation?
This antibody clone is manufactured by Abcam. If you require a custom buffer formulation or conjugation for your experiments, please contact orders@abcam.com
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
ASAH1 also known as acid ceramidase or alkaline ceramidase is an enzyme that plays a role in the hydrolysis of ceramides into sphingosine and free fatty acids. It has a mass of approximately 55 kDa. This enzyme is primarily found in lysosomes cellular organelles that manage waste. ASAH1 is expressed in various tissues including liver heart brain and skin illustrating its widespread distribution in the body.
Biological function summary
ASAH1 influences several important cellular processes by controlling the levels of ceramide and sphingosine. These lipids are not just structural components of membranes; they participate actively in cell signaling. ASAH1 exists as part of a larger complex that includes other enzymes involved in sphingolipid metabolism. Changes in ceramide levels influence apoptosis and cell proliferation indicating ASAH1's role as a regulator in these processes.
Pathways
ASAH1 is central to the sphingolipid metabolism pathway. This pathway is interconnected with the apoptosis signaling pathway. By converting ceramide to sphingosine ASAH1 links the complex ceramide/sphingosine balance affecting cell survival and death decisions. It interacts with other enzymes such as sphingosine kinase 1 and ceramide synthases which further maintain the dynamic regulation between sphingosine and ceramide levels.
ASAH1 is linked to conditions such as Farber disease and spinal muscular atrophy. These disorders result from dysfunctional ceramide metabolism causing cellular and systemic impacts due to excessive ceramide accumulation. Proteins like acid sphingomyelinase are related to ASAH1's role in these diseases as both contribute to sphingolipid balance in cells. Understanding ASAH1 and its pathways provides insights into potential therapeutic targets for these sphingolipid-related disorders.